Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: Can cytology specimens take the place of tissue sections?

Oncology Reports

Volumn 15, Issue 4, 2006, Pages 803-808

  Sumiyoshi, Kazuhiro ^a   Shibayama, Yuro ^a   Akashi, Shizuka ^a   Nohara, Takehiro ^a   Iwamoto, Mitsuhiko ^a   Kobayashi, Toshihiro ^a   Nishimura, Haruto ^a   Yoshinaka, Ryoji ^a   Harada, Tomoaki ^a   Tanigawa, Nobuhiko ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Chromogenic in situ hybridization; Fine needle aspiration cytology specimen; Gene amplification; HER2; Invasive breast cancer; Tissue section

Indexed keywords

EGFR2 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER INVASION; CHROMOSOME 17; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; METABOLISM; METHODOLOGY; MICROTOMY; MIDDLE AGED; NEEDLE BIOPSY; PAGET NIPPLE DISEASE; PATHOLOGY; REPRODUCIBILITY; TISSUE FIXATION;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MICROTOMY; MIDDLE AGED; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; TISSUE FIXATION;

EID: 33746429204     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.4.803     Document Type: Article

References (21)

1. Pegram M, Hsu S, Lewis G, et al: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241-2251, 1999. (Pubitemid 29186925)
2. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002. (Pubitemid 34111379)
3. Tsuda H, Akiyama F, Terasaki H, et al: Detection of HER2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer 92: 2965-2974, 2001. (Pubitemid 33136190)
4. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001. (Pubitemid 32222155)
5. Ross JS and Fletcher JA: HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 112: S53-S67, 1999. (Pubitemid 30219464)
6. Shak S: Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2 overexpressing metastatic breast cancer. Herceptin multinational investigator study group. Cancer Res 6: 71-77, 1999.
7. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety humanized anti-HER2 overexpression in metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999. (Pubitemid 29415219)
8. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987. (Pubitemid 17231334)
9. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in breast and ovarian cancer. Science 244: 707-712, 1989. (Pubitemid 19147683)
10. Corkill ME and Katz R: Immunocytochemical staining of c-erbB-2 oncogene in fine-needle aspirates of breast carcinoma: a comparison with tissue sections and other breast cancer prognostic factors. Diagn Cytopathol 11: 250-254, 1994. (Pubitemid 24341238)
11. Troncone G, Panico L, Vetrani A, et al: C-erbB-2 expression in FNAB smears and matched surgical specimens of breast cancer. Diagn Cytopathol 14: 135-139, 1996. (Pubitemid 26104488)
12. Troncone G, Zeppa P, Fulciniti F, et al: C-erbB-2 expression and DNA ploidy status in breast cancer cells obtained by fine needle aspiration (FNA). Cytopathol 4: 195-205, 1993. (Pubitemid 23258317)
13. Tiniakos DG, Robinson KB, Greenwood H, et al: c-erb B-2 and P53 expression in breast cancer fine needle aspirates. Cytopathology 7: 178-186, 1996. (Pubitemid 26186806)
14. Solomides CC, Zimmerman R and Bibbo M: Semiquantitative assessment of c-erbB-2 (HER2) status in cytology specimens and tissue sections from breast carcinoma. Anal Quant Cytol Histol 21: 121-125, 1999. (Pubitemid 29181217)
15. Arnould L, Denoux Y, MacGrogan G, et al: Agreement between chromogenic in situ hybridization (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 88: 1587-1591, 2003. (Pubitemid 36713787)
16. Dandachi N, Dietze O and Hauser-Kronberger C: Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest 82: 1007-1014, 2002.
17. Tanner M, Gancberg D, Di Leo A, et al: Chromogenic in situ hybridization: a pratical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 157: 1467-1472, 2000.
18. Diaz LK, Gupta R, Kidwai N, et al: The use of TMA for interlaboratory validation of FISH testing for detection of HER2 gene amplification in breast cancer. J Histochem Cytochem 52: 501-507, 2004. (Pubitemid 38420384)
19. Gupta D, Middleton LP, Whitaker MJ, et al: Comparison of fluorescence and chromogenic in situ hybridization for detection of HER2/neu oncogene in breast cancer. Am J Clin Pathol 119: 381-387, 2003. (Pubitemid 37047861)
20. Zhao J, Wu R, Au A, et al: Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol 15: 657-665, 2002. (Pubitemid 34666470)
21. Kumamoto H, Sasano H, Taniguchi T, et al: Chromogenic in situ hybridization analysis of HER2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy. Pathol Int 51: 579-584, 2001.